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We read with interest the article recently published by
Ashraf and colleagues [1]. The authors evaluated the prognos-
tic role of platelet count in patients with community-acquired
pneumonia (CAP) and found a significant relation between
both thrombocytopenia and thrombocytosis and the CURB-
65 score (confusion, urea, respiratory rate, arterial blood pres-
sure and age) as a score for severity of CAP.
Despite the efficacy of modern treatment, CAP is the lead-
ing cause of death due to infection [2]. Prognostic scores, like
the CURB-65 score and the pneumonia severity index have
been developed and validated to estimate the risk of adverse
outcome and to register a patient with CAP for hospital admis-
sion [2,3]. Biomarkers are also useful tools in the diagnosis,
prognostics and follow-up treatment of CAP. Procalcitonin
and C-reactive protein are commonly used biomarkers in
CAP, as indicators of severity of disease and predictors of
mortality [4]. Since CAP is an infectious disease, commonly-
used laboratory parameters include the C-reactive protein,
white blood cell count, and procalcitonin. However, recent
studies showed that cardiac complications are common in
patients with CAP, and cardiovascular biomarkers are found
to be superior compared to inflammatory markers, especially
for the determination of long-term prognosis in CAP [5,6]. Ele-
vated levels of natriuretic peptides and troponins are reported
to be common and are associated with a higher risk of adverse
outcome in CAP. Therefore, we would be grateful if the
authors have and would provide the data regarding troponin,
natriuretic peptide and procalcitonin levels on admission and
their relationship with platelet counts and the severity of the
disease in patients with CAP.
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